Evolocumab in STEMI or NSTEMI (AMUNDSEN-real)

Phase 4, randomised, open-label trial in myocardial infarction (MI) comparing Evolocumab + SOC with Standard of care (SOC) (2 arms). Primary endpoints: LDL-C reduction of >= 50% from baseline and a final LDL-C of <1.4 mmol/L (<55 mg/dL) at 12 months and Composite endpoint of death (any cause) or any unplanned hospitalization for a CV reason at 12 months. Started Sep 2021; status: active, not recruiting.